BioNTech
NEWS
A current Phase III trial of the Pfizer-BioNTech COVID-19 vaccine has confirmed the protection remains high for at least six months after the second dose. In a statement, Pfizer and BioNTech reported the vaccine was 91.3% effective against the disease.
The two companies announced data from a Phase III study which showed 100% efficacy and robust antibody responses in patients ages 12 -15 who received the BNT162b2 vaccine.
Between the Moderna and Pfizer-BioNTech COVID-19 vaccines, there are two mRNA therapeutics on the market … the only two.
With the ongoing global pandemic, BioNTech and Pfizer announced that they will be boosting their manufacturing capacity of the COVID-19 vaccine to 2.5 billion for 2021.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 9, 2021.
There was a little bit of positive COVID-19 news to report today. Here’s a look.
The Russian government is attempting to cast a negative light on the COVID-19 vaccine developed by Pfizer and BioNTech, as well as other vaccines, in order to boost sales of its own vaccine, Sputnik V, the government charged.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 2, 2021.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 23, 2021.
JOBS
IN THE PRESS